Better Antibodies By Design - Jefferies London Healthcare Conference November 15, 2017 - Genmab
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Better Antibodies By Design Jefferies London Healthcare Conference November 15, 2017
Forward Looking Statement
This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend”
and “plan” and similar expressions identify forward looking statements. All statements other than statements
of historical facts included in this presentation, including, without limitation, those regarding our financial
position, business strategy, plans and objectives of management for future operations (including
development plans and objectives relating to our products), are forward looking statements. Such forward
looking statements involve known and unknown risks, uncertainties and other factors which may cause our
actual results, performance or achievements to be materially different from any future results, performance or
achievements expressed or implied by such forward looking statements. Such forward looking statements
are based on numerous assumptions regarding our present and future business strategies and the
environment in which we will operate in the future. The important factors that could cause our actual results,
performance or achievements to differ materially from those in the forward looking statements include,
among others, risks associated with product discovery and development, uncertainties related to the
outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues
resulting from the administration of our products in patients, uncertainties related to product manufacturing,
the lack of market acceptance of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render our products obsolete, and other
factors. Further, certain forward looking statements are based upon assumptions of future events which may
not prove to be accurate. The forward looking statements in this document speak only as at the date of this
presentation.
2
Genmab At-A-Glance
Vision: By 2025, our own product has
transformed cancer treatment and we have a
pipeline of knock-your-socks off antibodies
DARZALEX® Tisotumab vedotin DuoBody® Platform Solid financial
Arzerra® HuMax®-AXL-ADC HexaBody® Tech. base
2 marketed products 2 exciting proprietary 2 proprietary next Aim to own at least
generating royalty clinical programs gen. technologies for 50% of product rights
income robust pre-clinical Allows for building
pipeline capabilities to market
own product in future
3
Antibody Innovation Powerhouse
Creating Value for Stakeholders
Antibody expertise
Innovation engine
DuoBody platform
HexaBody platform
Strategic collaborations
4
Innovative Clinical & Pre-clinical Pipeline
Further Development for Marketed Products
Product Disease Indications Development Phase
Pre-
I I/II II III
Clinical
Daratumumab BTD (2 - MM) Multiple myeloma (MM)
Target: CD38
Partner: Janssen Amyloidosis
Natural Killer /T-Cell
Lymphoma (NKTCL), Nasal
Type
Myelodysplastic Syndromes
(MDS)
Solid tumors
Ofatumumab BTD (CLL) Follicular lymphoma (FL)
Target: CD20
Indication: Cancer
Partner: Novartis
Ofatumumab (OMB157) Relapsing multiple sclerosis
Target: CD20 (RMS) (SubQ)
Indication: AI
Partner: Novartis
5
Innovative Clinical & Pre-clinical Pipeline
Product Disease Indications Development Phase
Pre-
I I/II II III
Clinical
Tisotumab vedotin Solid cancers
Target: TF
HuMax-AXL-ADC Solid cancers
Target: AXL
Teprotumumab (RV001) BTD Graves’ orbitopathy
Target: IGF-1R, Partner: Horizon
Pharma
AMG 714 Celiac Disease
Target: IL-15, Partner: Celimmune
ADCT-301 (HuMax-TAC-ADC) Lymphoma
Target: CD25, Partner: ADCT
Acute myeloid leukemia (AML) or
acute lymphoblastic leukemia
(ALL)
JNJ-61186372 Non-small-cell lung cancer
Targets: EGFR, cMet, Partner: Janssen (NSCLC)
JNJ-63709178 Acute Myeloid Leukemia (AML)
Targets: CD3, CD123, Partner: Janssen
JNJ-64007957 Relapsed or refractory MM
Targets: BCMA, CD3, Partner: Janssen
>20 Active Pre-clinical programs incl. Proprietary programs: HuMab,
HexaBody-DR5/DR5, DuoBody HuMab-ADC, DuoBody, DuoBody-
CD3xCD20 ADC & HexaBody
Partnered programs: HuMab,
6
DuoBody & HexaBody
Daratumumab (Marketed as DARZALEX®)
Approved in US & EU
First-in-class antibody targeting CD38 – 2 FDA BTDs
Marketed as monotherapy in US & EU for double refractory MM
Approved in US, EU & Japan in combo. w/ Revlimid & dex or
Velcade & dex for relapsed / refractory MM
Approved in the US in combo. w/ Pomalyst & dex for pts w/ MM
who have received at least 2 prior therapies
Industry sponsored clinical studies ongoing in MM, NKT-cell
lymphoma, MDS, amyloidosis and solid tumors
Blockbuster potential – growing royalty income
Royalty rate: 12% - 20%
Collaboration w/ Janssen Biotech
Up to $1bn in dev., reg. & sales milestones, Janssen
responsible for all costs assoc. w/ dev. & commercialization
7
Expansive Daratumumab Clinical Development: MM
Disease Stage Therapy Development Phase
No. Pre-
I I/II II III
Pts Clinical
High Risk Smoldering Subcutaneous 360 AQUILA
Monotherapy 126
CENTAURUS
Front line (transplant & non-
transplant)
Dara + VMP
Dara + VMP (Asia Pacific)
706
ALCYONE
192
Dara + Rd 744
MAIA
Dara + VTd
Dara + RVd
1,080
CASSIOPEIA
GRIFFIN
216
Multi combo study (6 arms) 250 EQUULEUS
Relapsed or Refractory Dara + Vd (China) 210
Dara + Kd 450 CANDOR
Dara + Pom + d 302 APOLLO
Subcutaneous vs IV 480 COLUMBA
Dara + Imfinzi* 264 FUSION
Dara + Keytruda 57
V = bortezomib , MP = melphalan-
prednisone , T = thalidomide , d= Dara + Venclexta + d +/- V 90
dexamethasone, R = lenalidomide, K =
Kyprolis, Pom = Pomalyst
Fully recruited *Trials on partial clinical Dara + Opdivo* 375
hold, unrelated to daratumumab
Maintenance integrated into some study
protocols Dara + Tecentriq* 288 8
Select Studies
Expansive Daratumumab Clinical Development
Other Indications
Disease Stage Therapy Development Phase
No.
Pts
Pre-Clinical I I/II II III
Amyloidosis Dara SC + CyBorD 370 ANDROMEDA
NKTCL (nasal type) Monotherapy 32 VOLANS
Colon cancer Dara + Opdivo 340
MDS Dara or talacotuzumab 31
NSCLC Dara + Tecentriq 96 CALLISTO
NSCLC, pancreatic, Dara + Opdivo
triple neg. breast 120
cancers
Virus associated Dara + Opdivo
500
tumors
9
CyBorD = cyclophosphamide, bortezomib and dexamethasone
Ofatumumab (Arzerra®)
Human antibody targeting CD20
Two Phase III studies in relapsing MS ongoing
MS Advantages: Dosing
Better disease management, subcutaneous dosing
MS Advantages: Attributes
Potential for low immunogenicity, manageable safety profile
Marketed in various territories for certain CLL indications*
Collaboration with Novartis
Cash flow positive for Genmab
10
*See local country prescribing information for precise indicationsClinical Projects: Tisotumab vedotin
Phase I/II studies in Patients with Solid Tumors
Fully human antibody-drug conjugate (ADC)
Targets Tissue Factor (TF)
Therapeutic potential in broad range of solid tumors
Studies ongoing in solid tumors
Indications incl. gynecologic (ovarian, cervical, and
endometrial) cancers, prostate, bladder, &
esophageal cancers, NSCLC & SCCHN
Encouraging preliminary safety & efficacy data
Promising data in pts w/ cervical cancer
Based on data, looking at further dev. in indication
Co-development with Seattle Genetics
11Clinical Projects: HuMax-AXL-ADC
Efficacy in in vivo Tumor Model
Human ADC
Targets tumor-associated AXL
Therapeutic potential in solid tumors
First-in-human Phase I/II study
Indications incl. gynecologic (ovarian, cervical, &
endometrial) cancers, thyroid cancer, NSCLC and
melanoma
ADC technology licensed from Seattle Genetics
12
Malignant Melanoma: AXL expression indicated by brown stainingNext in the Clinic: 2017 IND Candidates
HexaBody-DR5/DR5 DuoBody CD3xCD20
• Targets DR5 for cancer • Humanized IgG1 bispecific
therapy antibody
• Potentially effective in multiple • Activates T cells to kill CD20+
tumor types tumor cells
DR5 activation induces cell death 13Genmab Proprietary Innovative Pipeline
Potential INDs in next 4 years
Technology product 2017 2018 2019 2020
HexaBody HexaBody‐DR5/DR5
DuoBody DuoBody‐CD3xCD20
HexaBody DuoHexaBody
DuoBody DuoBody‐CD3xX
Immuno‐Oncology DuoBody‐A
[>10 progr.]*
DuoBody‐B
DuoBody‐C
DuoBody‐D
*: Aduro Biotech &
BioNTech DuoBody‐E
Pre-clinical pipeline targeting at least 4 leapfrog INDs in next 4 years
14Cutting Edge Capabilities: Proprietary
Technologies to create Leapfrog Drugs
DuoBody
• Efficient & versatile bispecific Ab platform
• Applicable to any antibody from any platform
• Regular IgG format
• Large scale production validated
• No developability liabilities
• Robotized bispecific library generation
• Multiple ongoing collaborations incl. with Novartis,
Novo Nordisk, Gilead & Janssen Biotech
HexaBody
• Robust effector function enhanced Ab
• Enables antibodies to readily form
clusters of 6 (hexamers)
• Induces & enhances target cell killing
after binding (CDC and apoptosis)
• Creates innovative products in cancer
& infectious diseases
• Collaborations with Humabs BioMed,
Agenus and others 15Well-Capitalized Biotech – 2017 Guidance
2017 Expense Base
Income Statement DKKM USDM*
DKK 1,050M ($161M)
Revenue 1,950 – 2,150 309 - 341
Operating expenses (1,000) – (1,100) (159) – (174) DKK 159M
($25M)
Operating income 900 – 1,100 143 - 174 15% DKK 91M
($14M)
Cash position at end DKK 239M 9%
>4,500 >714 ($38M)
of year**
*USD 1.00 = DKK 6.3038 23%
**Cash, cash equivalents and marketable securities
2017 Guidance – Nov 8, 2017
DARZALEX sales
• Genmab’s estimate of DARZALEX net sales USD 1.1-1.3 billion
Revenue mid-point DKK 2,050M 53%
• DARZALEX royalties DKK 1,000M
• DARZALEX milestones DKK 800M
DKK 561M
• Quality of revenue improving
Expense mid-point DKK 1,050 Project Costs ($89M)
• Expense increase DKK 287M, +38% Salaries
• Continued investment in our clinical & pre-clinical pipeline
• 8 pipeline projects drive ~DKK 440M, 42% of total expense Support Svcs
Depr. & Stock Comp. 162017 Goals
Maximizing Differentiated Product Portfolio Value
Priority Targeted Milestone
Maximize daratumumab » EMA decision & launch in 2nd line+ in multiple myeloma (MM)
progress relapsed / refractory setting
» FDA decision in 3rd line MM setting (daratumumab + POM)
» Phase III MM interim efficacy analysis in frontline (Alcyone trial)
» Start Phase III subcutaneous trial
» Start trials in solid tumors and non-MM blood cancers
» Report non-MM clinical data
Optimize ofatumumab 2018* » Phase III refractory follicular lymphoma headline results
value
Strengthen differentiated » Phase I/II tisotumab vedotin data
product pipeline » Progress HuMax-AXL-ADC Phase I/II clinical trial
» IND/CTA submission HexaBody-DR5/DR5
» IND/CTA submission DuoBody-CD3xCD20
» Progress pre-clinical pipeline
Broaden partnership » Enter new technology collaborations
portfolio with next » Progress partnered programs
generation technologies
Disciplined financial » Execute controlled company growth with selective investments in
management product pipeline
17
*Data read out now expected to occur in 2018.Creating Value for Patients & Shareholders
Building on 3 central pillars:
Focus, Innovation & Execution
Robust pre-clinical Building commercial
2 marketed products
pipeline expertise
2 proprietary early World-class antibody
Solid financials
stage clin. programs & R&D expertise
2 proprietary Strategic
Proven track record
technologies collaborations
18www.genmab.com
You can also read
